Sodium-glucose co-transporter 2 inhibitors (SGLT2i) were initially discovered as a compound present in roots, leaves and fruits of the apple tree in 1835. However, it was not until the beginning of the 21st century that their clinical application in humans was introduced, when chemical research achieved improvements in half-life, hydrolysis resistance and greater affinity for SGLT2 receptors.
